Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2019

06.03.2019 | Clinical trial

What does risk of future cancer mean to breast cancer patients?

verfasst von: Karen Kaiser, Kenzie A. Cameron, Jennifer Beaumont, Sofia F. Garcia, Leilani Lacson, Margaret Moran, Lindsey Karavites, Chiara Rodgers, Swati Kulkarni, Nora M. Hansen, Seema A. Khan

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Newly diagnosed breast cancer patients greatly overestimate their risk of developing contralateral breast cancer (CBC). Better understanding of patient conceptions of risk would facilitate doctor–patient communication and surgical decision making. In this mixed methods study, we prospectively examined breast cancer patients’ perceived risk of future cancer and the reported factors that drove their risk perceptions.

Methods

Women age 21–60 diagnosed with breast cancer without a BRCA mutation or known distant metastases completed a study interview between surgical consult and surgical treatment. Participants completed a 12-item Perceived Risk Questionnaire, which assessed 10-year and lifetime risks of ipsilateral local recurrence, CBC, and distant recurrence. Patients provided qualitative explanations for their answers.

Results

Sixty-three patients completed study interviews (mean age 50.3). Participants were primarily White (85.7%) and 90.5% had attended college. Patients estimated their 10-year risk of CBC as 22.0%, nearly 4 times the established 10-year risk. Women attributed their risk perceptions to “gut feelings” about future cancer, even when women knew those feelings contradicted medically established risk. Perceptions of risk also reflected beliefs that cancer is random and that risk for local recurrence, CBC, and distant recurrence are the same.

Conclusions

Our findings point to the need for novel ways of presenting factual information regarding both risk of recurrence and of new primary cancers, as well as the necessity of acknowledging cognitive and affective processes many patients use when conceptualizing risk. By differentiating women’s intuitive feelings about risk from their knowledge of medically estimated risk, doctors can enhance informed decision making.
Literatur
1.
Zurück zum Zitat Boughey JC, Attai DJ, Chen SL, Cody HS, Dietz JR, Feldman SM, Greenberg CC, Kass RB, Landercasper J, Lemaine V, MacNeill F, Margenthaler JA, Song DH, Staley AC, Wilke LG, Willey SC, Yao KA (2016) Contralateral prophylactic mastectomy consensus statement from the American society of breast surgeons: additional considerations and a framework for shared decision making. Ann Surg Oncol 23:1–6. https://doi.org/10.1245/s10434-016-5408-8 CrossRef Boughey JC, Attai DJ, Chen SL, Cody HS, Dietz JR, Feldman SM, Greenberg CC, Kass RB, Landercasper J, Lemaine V, MacNeill F, Margenthaler JA, Song DH, Staley AC, Wilke LG, Willey SC, Yao KA (2016) Contralateral prophylactic mastectomy consensus statement from the American society of breast surgeons: additional considerations and a framework for shared decision making. Ann Surg Oncol 23:1–6. https://​doi.​org/​10.​1245/​s10434-016-5408-8 CrossRef
9.
Zurück zum Zitat National Comprehensive Cancer Network (2016) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Breast Cancer National Comprehensive Cancer Network (2016) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Breast Cancer
17.
Zurück zum Zitat Anderson SJ, Wapnir I, Dignam JJ, Fisher B, Mamounas EP, Jeong JH, Geyer CE Jr, Wickerham DL, Costantino JP, Wolmark N (2009) Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol 27(15):2466–2473. https://doi.org/10.1200/JCO.2008.19.8424 CrossRefPubMedPubMedCentral Anderson SJ, Wapnir I, Dignam JJ, Fisher B, Mamounas EP, Jeong JH, Geyer CE Jr, Wickerham DL, Costantino JP, Wolmark N (2009) Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol 27(15):2466–2473. https://​doi.​org/​10.​1200/​JCO.​2008.​19.​8424 CrossRefPubMedPubMedCentral
19.
23.
Zurück zum Zitat Lipkus IM, Rimer BK, Strigo TS (1996) Relationships among objective and subjective risk for breast cancer and mammography stages of change. Cancer Epidemiol Biomark Prevent 5(12):1005–1011 Lipkus IM, Rimer BK, Strigo TS (1996) Relationships among objective and subjective risk for breast cancer and mammography stages of change. Cancer Epidemiol Biomark Prevent 5(12):1005–1011
27.
Zurück zum Zitat Lerman C, Biesecker B, Benkendorf J, Al E (1997) Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing. J Natl Cancer Inst 89:148–157CrossRefPubMed Lerman C, Biesecker B, Benkendorf J, Al E (1997) Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing. J Natl Cancer Inst 89:148–157CrossRefPubMed
Metadaten
Titel
What does risk of future cancer mean to breast cancer patients?
verfasst von
Karen Kaiser
Kenzie A. Cameron
Jennifer Beaumont
Sofia F. Garcia
Leilani Lacson
Margaret Moran
Lindsey Karavites
Chiara Rodgers
Swati Kulkarni
Nora M. Hansen
Seema A. Khan
Publikationsdatum
06.03.2019
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2019
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-019-05182-3

Weitere Artikel der Ausgabe 3/2019

Breast Cancer Research and Treatment 3/2019 Zur Ausgabe

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.